MRKR Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals has a net margin of -- compared to Marker Therapeutics's net margin of --. Marker Therapeutics's return on equity of -- beat Armata Pharmaceuticals's return on equity of --.

Marker Therapeutics has a consensus price target of $19.00, signalling upside risk potential of 510.93%. On the other hand Armata Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 278.38%. Given that Marker Therapeutics has higher upside potential than Armata Pharmaceuticals, analysts believe Marker Therapeutics is more attractive than Armata Pharmaceuticals.

Marker Therapeutics has a beta of 1.484, which suggesting that the stock is 48.378% more volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.851, suggesting its less volatile than the S&P 500 by 14.895%.

Marker Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Marker Therapeutics pays -- of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend.

Marker Therapeutics quarterly revenues are --, which are smaller than Armata Pharmaceuticals quarterly revenues of --. Marker Therapeutics's net income of -$2.3M is higher than Armata Pharmaceuticals's net income of -$5.5M. Notably, Marker Therapeutics's price-to-earnings ratio is -- while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Marker Therapeutics is -- versus 670.23x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of -- compared to Marker Therapeutics's net margin of --. Marker Therapeutics's return on equity of -- beat Perspective Therapeutics's return on equity of --.

Marker Therapeutics has a consensus price target of $19.00, signalling upside risk potential of 510.93%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 406.27%. Given that Marker Therapeutics has higher upside potential than Perspective Therapeutics, analysts believe Marker Therapeutics is more attractive than Perspective Therapeutics.

Marker Therapeutics has a beta of 1.484, which suggesting that the stock is 48.378% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.195, suggesting its more volatile than the S&P 500 by 19.546%.

Marker Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Marker Therapeutics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Marker Therapeutics quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Marker Therapeutics's net income of -$2.3M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, Marker Therapeutics's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Marker Therapeutics is -- versus 17.23x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of -- compared to Marker Therapeutics's net margin of 10.05%. Marker Therapeutics's return on equity of -- beat Electromed's return on equity of 15.62%.

Marker Therapeutics has a consensus price target of $19.00, signalling upside risk potential of 510.93%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could grow by 11.68%. Given that Marker Therapeutics has higher upside potential than Electromed, analysts believe Marker Therapeutics is more attractive than Electromed.

Marker Therapeutics has a beta of 1.484, which suggesting that the stock is 48.378% more volatile than S&P 500. In comparison Electromed has a beta of 0.314, suggesting its less volatile than the S&P 500 by 68.592%.

Marker Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Marker Therapeutics pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Marker Therapeutics quarterly revenues are --, which are smaller than Electromed quarterly revenues of $14.7M. Marker Therapeutics's net income of -$2.3M is lower than Electromed's net income of $1.5M. Notably, Marker Therapeutics's price-to-earnings ratio is -- while Electromed's PE ratio is 41.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Marker Therapeutics is -- versus 4.62x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -- compared to Marker Therapeutics's net margin of 18.02%. Marker Therapeutics's return on equity of -- beat Protalix BioTherapeutics's return on equity of -29.54%.

Marker Therapeutics has a consensus price target of $19.00, signalling upside risk potential of 510.93%. On the other hand Protalix BioTherapeutics has an analysts' consensus of -- which suggests that it could grow by 644.68%. Given that Protalix BioTherapeutics has higher upside potential than Marker Therapeutics, analysts believe Protalix BioTherapeutics is more attractive than Marker Therapeutics.

Marker Therapeutics has a beta of 1.484, which suggesting that the stock is 48.378% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.711, suggesting its less volatile than the S&P 500 by 28.881%.

Marker Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Marker Therapeutics pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Marker Therapeutics quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $18M. Marker Therapeutics's net income of -$2.3M is lower than Protalix BioTherapeutics's net income of $3.2M. Notably, Marker Therapeutics's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 121.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Marker Therapeutics is -- versus 3.23x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.